LBPS Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 saus. 1970 @ 03:00):

Stats
Dzisiejszy wolumen	3 914.00
Średni wolumen	11 314.00
Kapitalizacja rynkowa	0.00
EPS	$0 ( 2022-03-31 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.220 (13.33%)

Wolumen Korelacja

Długi: 0.32 (neutral)

Krótki: -0.32 (neutral)

Signal:(22.657) Neutral

4D pharma plc Korelacja

10 Najbardziej pozytywne korelacje
UTHR	0.931
GOOD	0.925
ALXO	0.917
HALO	0.917
BEAT	0.917
BCYC	0.916
CBNK	0.915
PSHG	0.914
EAR	0.91
IBRX	0.908

10 Najbardziej negatywne korelacje
DAKT	-0.934
AXON	-0.914
DUOL	-0.912
LMNR	-0.908
DAIO	-0.901
OSPN	-0.901
BWMX	-0.9
ALTR	-0.899
OMAB	-0.897
ANSS	-0.897

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

4D pharma plc Korelacja - Waluta/Towar

0.08
( neutral )

0.18
( neutral )

0.00
( neutral )

0.33
( neutral )

-0.29
( neutral )

-0.22
( neutral )

4D pharma plc Finanse

Annual	2021
Przychody:	$718 000
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.520

FY	2021
Przychody:	$718 000
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.520

FY	2020
Przychody:	$534 000
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.824

FY	2019
Przychody:	$211 000
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-2.94

Financial Reports:

No articles found.

4D pharma plc

4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.